US Food And Drug Administration Accepts For Review AstraZeneca's Supplemental Biologics License Application For Self-Administration Of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal)
Portfolio Pulse from Benzinga Newsdesk
The US Food and Drug Administration (FDA) has accepted AstraZeneca's supplemental biologics license application for self-administration of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal).
October 24, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's application for self-administration of FLUMIST QUADRIVALENT has been accepted by the FDA. This could potentially increase the accessibility and usage of the vaccine.
The acceptance of AstraZeneca's application by the FDA is a positive development for the company. If approved, it could potentially increase the accessibility and usage of the FLUMIST QUADRIVALENT vaccine, which would likely have a positive impact on AstraZeneca's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100